

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/22 - Basic Clinical Chemistry - Serum

Deadline: 08.04.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{Tot}	N _{Out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(1) Sodium					366								0								366	363	99%
Samples and groups	[mmol/L]																						
Sample A		119	1,8	1,5	366								0	CRV	119,7	1,8	5%	113	126	366	365	100%	
(2) Indirect ISE		119	1,8	1,5	324	0															324		
(3) Direct ISE		120	2,6	2,2	41	0															41		
Other					1	0															1		
														1x 99									
Sample B		128	2,0	1,6	366								0	CRV	128,3	1,9	5%	121	135	366	364	99%	
(2) Indirect ISE		128	1,9	1,5	324	0															324		
(3) Direct ISE		130	2,9	2,3	41	0															41		
Other					1	0															1		
														1x 99									
(2) Potassium					366								0								366	356	97%
Samples and groups	[mmol/L]																						
Sample A		4,35	0,08	2,0	366								0	CRV	4,322	0,065	7%	4,01	4,63	366	365	100%	
(2) Indirect ISE		4,34	0,08	1,9	325	0															325		
(3) Direct ISE		4,38	0,11	2,5	40	0															40		
Other					1	0															1		
														1x 99									
Sample B		3,39	0,06	1,8	366								0	CRV	3,353	0,050	7%	3,11	3,59	366	356	97%	
(2) Indirect ISE		3,39	0,05	1,7	325	0															325		
(3) Direct ISE		3,42	0,08	2,5	40	0															40		
Other					1	0															1		
														1x 99									
(3) Chloride					366								366	358	98%						0		
Samples and groups	[mmol/L]																						
Sample A		97,8	3,0	3,1	366	CVP	97,8	0,39	7%	90,9	105	366	362	99%							0		
(3) Indirect ISE		97,8	3,2	3,2	327	0							327										
(4) Direct ISE		97,9	2,1	2,1	38	0							38										
Other					1	0							1										
														1x 99									
Sample B		112	3,0	2,7	366	CVP	112	0,38	7%	104	120	366	362	99%							0		
(3) Indirect ISE		112	3,0	2,7	327	0							327										
(4) Direct ISE		112	2,7	2,4	38	0							38										
Other					1	0							1										
														1x 99									
(4) Calcium					336								0								336	329	98%
Samples and groups	[mmol/L]																						
Sample A		1,81	0,05	2,7	336								0	CRV	1,797	0,027	8%	1,65	1,95	336	333	99%	
(2) Phot. with o-cresolftalexon		1,80	0,05	2,8	27	0															27		
(3) Photom. with arsenazo III		1,82	0,06	3,5	198	0															198		

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/22 - Basic Clinical Chemistry - Serum

Deadline: 08.04.2022

Test	[unit]	Comparability										Traceability										
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(4) Calcium	[mmol/L]				336							0								336	329	98%
Samples and groups																						
Sample A		1,81	0,05	2,7	336							0	CRV	1,797	0,027	8%	1,65	1,95	336	333	99%	
(4) Photomet. with NM-BAPTA		1,81	0,03	1,8	109	0														109		
Other					2	0															2	
Sample B		2,91	0,06	2,3	336							0	2x6 CRV	2,926	0,047	8%	2,69	3,17	336	332	99%	
(2) Phot. with o-cresolftalexon		2,90	0,07	2,7	27	0														27		
(3) Photom. with arsenazo III		2,89	0,07	2,5	198	0														198		
(4) Photomet. with NM-BAPTA		2,94	0,04	1,7	109	0														109		
Other					2	0															2	
(5) Inorganic phosphate	[mmol/L]				326							326	315	97%								0
Samples and groups																						
Sample A		1,52	0,04	2,9	326	CVP	1,52	,0060	10%	1,36	1,68	326	321	98%								0
(1) UV-molybdate method		1,52	0,04	2,9	317	1						317										
(3) Molybdate-vanadate method		1,52	0,05	3,4	5	0						5										
Other					4	0						4										
Sample B		1,03	0,03	3,1	326	4x2 CVP	1,03	,0044	10%	0,927	1,14	326	318	98%								0
(1) UV-molybdate method		1,03	0,03	3,2	317	0						317										
(3) Molybdate-vanadate method		1,02	0,03	3,7	5	0						5										
Other					4	0						4										
(6) Iron	[µmol/L]				315							315	313	99%								0
Samples and groups																						
Sample A		21,2	0,68	3,2	315	CVP	21,2	0,094	15%	18	24,4	315	314	100%								0
(2) Method with ferrozine/ferene		21,2	0,72	3,4	274	0						274										
(4) Method with TPTZ		21,0	0,45	2,1	41	0						41										
Sample B		41,0	1,3	3,3	315	CVP	41	0,19	15%	34,8	47,2	315	313	99%								0
(2) Method with ferrozine/ferene		41,1	1,3	3,3	274	0						274										
(4) Method with TPTZ		40,7	1,3	3,1	41	0						41										
(7) Magnesium	[mmol/L]				317							0								317	312	98%
Samples and groups																						
Sample A		1,18	0,04	3,7	317							0	CRV	1,171	0,018	15%	0,995	1,35	317	315	99%	
(2) Photometry		1,19	0,04	3,6	239	0														239		
(4) UV enzyme method		1,17	0,03	3,3	78	0															78	
Sample B		0,815	0,03	3,9	317							0	CRV	0,783	0,012	15%	0,665	0,901	317	314	99%	
(2) Photometry		0,824	0,02	3,4	239	0														239		
(4) UV enzyme method		0,787	0,02	3,2	78	0															78	
(8) Lithium	[mmol/L]				46							0								46	39	85%
Samples and groups																						
Sample A		0,988	0,04	4,1	46							0	CRV	1,01	0,015	12%	0,888	1,14	46	39	85%	
(1) Flame emission phot.		0,980	0,03	3,0	5	0															5	
(3) ISE		0,991	0,03	3,3	13	0															13	
(4) Photometry		0,985	0,05	5,3	25	0															25	

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/22 - Basic Clinical Chemistry - Serum

Deadline: 08.04.2022

Test	[unit]	Comparability										Traceability										
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(8) Lithium					46							0								46	39	85%
Samples and groups	[mmol/L]																					
Sample A		0,988	0,04	4,1	46							0	CRV	1,01	0,015	12%	0,888	1,14	46	39	85%	
Other					3	0														3		
Sample B		1,45	0,05	3,9	46							0	CRV	1,489	0,022	12%	1,31	1,67	46	45	98%	
(1) Flame emission phot.		1,42	0,02	1,6	5	0														5		
(3) ISE		1,46	0,06	4,1	13	0														13		
(4) Photometry		1,44	0,04	3,1	25	0														25		
Other					3	0														3		
													3x2									
(9) Total protein					347							0								347	344	99%
Samples and groups	[g/L]																					
Sample A		75,5	1,8	2,4	347							0	CRV	74,9	1,8	9%	68,1	81,7	347	344	99%	
(1) Biuret		75,5	1,8	2,4	347	0														347		
Sample B		71,2	1,7	2,4	347							0	CRV	72,1	1,7	9%	65,6	78,6	347	347	100%	
(1) Biuret		71,2	1,7	2,4	347	0														347		
(10) Albumin					342							342	337	99%								0
Samples and groups	[g/L]																					
Sample A		47,5	1,7	3,6	342	CVP	47,5	0,23	10%	42,7	52,3	342	340	99%								0
(1) BCG		47,6	1,6	3,4	321	0						321										
(2) BCP		45,5	1,4	3,1	21	0						21										
Sample B		45,1	1,5	3,4	342	CVP	45,1	0,20	10%	40,5	49,7	342	337	99%								0
(1) BCG		45,2	1,5	3,2	321	0						321										
(2) BCP		43,0	1,6	3,7	21	0						21										
(11) Osmolality					124								124	122	98%							0
Samples and groups	[mmol/kg]																					
Sample A		263	4,9	1,9	124	CVP	263	1,1	5%	249	277	124	124	100%								0
(1) Osmometer		263	4,9	1,9	122	0						122										
Other					2	0						2										
Sample B		299	5,0	1,7	124	CVP	299	1,1	5%	284	314	124	122	98%								0
(1) Osmometer		299	4,9	1,6	122	0						122										
Other					2	0						2										
(12) Lactate					150								150	143	95%							0
Samples and groups	[mmol/L]																					
Sample A		5,99	0,21	3,4	150	CVP	5,99	0,041	15%	5,09	6,89	150	146	97%								0
(1) UV enzyme method		5,97	0,20	3,4	59	0						59										
(2) Enzyme electrodes		6,09	0,30	4,9	10	0						10										
(3) Photometric enzyme method		6,00	0,20	3,3	80	0						80										
Other					1	0						1										
Sample B		2,01	0,09	4,6	150	CVP	2,01	0,018	15%	1,7	2,32	150	147	98%								0
(1) UV enzyme method		2,00	0,07	3,9	59	0						59										
(2) Enzyme electrodes		2,18	0,17	7,9	10	0						10										

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/22 - Basic Clinical Chemistry - Serum

Deadline: 08.04.2022

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(12) Lactate	[mmol/L]				150							150	143	95%							0		
Samples and groups																							
Sample B		2,01	0,09	4,6	150	CVP	2,01	0,018	15%	1,7	2,32	150	147	98%							0		
(3) Photometric enzyme method		2,00	0,09	4,5	80							80											
Other					1							1											
						1x0																	
(13) Bilirubin total	[µmol/L]				368																368	358	97%
Samples and groups																							
Sample A		22,9	2,5	11	368							0		CRV	21,8	0,50	21%	17,2	26,4	368	360	98%	
(1) Jendrassik-Gróf		23,3	2,5	11	50	0															50		
(2) DCA, DPD		22,6	2,6	11	274	0															274		
(4) Oxidation-reduction methods		23,9	1,7	7,1	42	0															42		
Other					2	0															2		
Sample B		28,7	2,9	10	368							0		2x99 CRV	27,7	0,70	21%	21,8	33,6	368	363	99%	
(1) Jendrassik-Gróf		29,3	2,9	10	50	0															50		
(2) DCA, DPD		28,4	2,9	10	274	0															274		
(4) Oxidation-reduction methods		30,1	2,1	6,9	42	0															42		
Other					2	0															2		
														2x99									
(15) Cholesterol	[mmol/L]				359							6	6	100%							353	345	98%
Samples and groups																							
Sample A		4,14	0,12	2,9	359							6	6	100%							353	350	99%
(1) Enzyme method CHOD-PAP		4,15	0,12	2,9	353	0								CRV	4,187	0,042	9%	3,81	4,57	353			
(1) Enzyme method CHOD-PAP; (149) Siemens (Dade, BN, Dimension)		3,82	0,22	5,8	6	0	CVPG	3,82	0,31	7%	3,55	4,09	6										
Sample B		3,89	0,12	3,0	359							6	6	100%							353	348	99%
(1) Enzyme method CHOD-PAP		3,89	0,11	2,9	353	1								CRV	3,906	0,039	9%	3,55	4,26	353			
(1) Enzyme method CHOD-PAP; (149) Siemens (Dade, BN, Dimension)		3,55	0,15	4,2	6	0	CVPG	3,55	0,21	7%	3,3	3,8	6										
(16) Glucose	[mmol/L]				372							0									372	367	99%
Samples and groups																							
Sample A		13,3	0,33	2,5	372							0		CRV	13,89	0,14	asym.	12,3	15,1	372	370	99%	
(1) GOD photometry		13,4	0,44	3,3	70	0															70		
(3) Method with hexokinase		13,2	0,30	2,3	299	0															299		
Other					3	0															3		
Sample B		3,79	0,10	2,7	372							0		3x2 CRV	3,89	0,039	asym.	3,46	4,21	372	368	99%	
(1) GOD photometry		3,84	0,13	3,3	70	0															70		
(3) Method with hexokinase		3,77	0,09	2,5	299	0															299		
Other					3	0															3		
														3x2									
(17) Uric acid	[µmol/L]				366							0									366	366	100%
Samples and groups																							
Sample A		299	8,9	3,0	366							0		CRV	305,5	3,1	12%	268	343	366	366	100%	
(2) Enzyme-photomet. m.		299	8,9	3,0	366	0															366		
Sample B		455	12	2,7	366							0		CRV	456,3	4,6	12%	401	512	366	366	100%	

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/22 - Basic Clinical Chemistry - Serum

Deadline: 08.04.2022

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(17) Uric acid	[µmol/L]				366							0									366	366	100%
Samples and groups																							
Sample B		455	12	2,7	366							0	CRV	456,3	4,6	12%	401	512		366	366	100%	
(2) Enzyme-photomet. m.		455	12	2,7	366	0															366		
Samples and groups																							
(18) Urea	[mmol/L]				369							0									369	362	98%
Samples and groups																							
Sample A		5,09	0,26	5,1	369							0	CRV	5,19	0,052	15%	4,41	5,97		369	363	98%	
(1) UV enzymatic m.(GMD)		5,09	0,26	5,1	365	0															365		
Other					4	0																4	
Samples and groups																							
Sample B		31,2	1,1	3,7	369							0	CRV	31,96	0,32	15%	27,1	36,8		369	367	99%	
(1) UV enzymatic m.(GMD)		31,1	1,1	3,7	365	0															365		
Other					4	0																4	
Samples and groups																							
(19) Creatinine	[µmol/L]				371							0									371	368	99%
Samples and groups																							
Sample A		397	14	3,6	371							0	CRV	390,3	3,9	13%	339	442		371	369	99%	
(1) Jaffe		400	19	4,7	168	0															168		
(3) Enzyme		395	11	2,7	203	0															203		
Samples and groups																							
Sample B		120	5,5	4,6	371							0	CRV	119,6	1,7	13%	104	136		371	369	99%	
(1) Jaffe		122	6,6	5,4	168	0															168		
(3) Enzyme		119	4,4	3,7	203	0															203		
Samples and groups																							
(20) Triacylglycerols	[mmol/L]				357							0									357	354	99%
Samples and groups																							
Sample A		1,24	0,04	3,9	357							0	CRV	1,244	0,012	15%	1,05	1,44		357	355	99%	
(1) Photometric enzyme (GPO-PAP)		1,24	0,04	3,9	346	0															346		
(2) Enzymatic UV method		1,24	0,04	3,7	11	0															11		
Samples and groups																							
Sample B		1,81	0,06	3,3	357							0	CRV	1,771	0,018	15%	1,5	2,04		357	356	100%	
(1) Photometric enzyme (GPO-PAP)		1,81	0,06	3,3	346	0															346		
(2) Enzymatic UV method		1,82	0,06	3,5	11	0															11		
Samples and groups																							
(21) ALP	[µkat/L]				364							358	352	98%							364	356	98%
Samples and groups																							
Sample A		8,92	0,76	8,6	364							358	354	99%	CRV	9,31	0,26	20%	7,44	11,2	364	357	98%
(3) IFCC method; (1) Abbott		9,19	0,40	4,4	90	0	CVPG	9,2	0,10	15%	7,82	10,6								90			
(3) IFCC method		8,92	0,76	8,6	363	0																363	
(3) IFCC method; (12) Beckman Coulter		9,78	0,16	1,6	5	0	CVPG	9,78	0,44	15%	8,31	11,3								5			
(3) IFCC method; (46) Erba Lachema		9,55	0,57	6,0	15	0	CVPG	9,55	0,36	15%	8,11	11								15			
(3) IFCC method; (49) BioVendor		8,77	0,54	6,2	11	0	CVPG	8,77	0,40	15%	7,45	10,1								11			
(3) IFCC method; (58) Beckman Coulter (AU)		10,1	0,41	4,1	45	0	CVPG	10,1	0,15	15%	8,58	11,7								45			
(3) IFCC method; (60) Roche		8,36	0,36	4,3	132	0	CVPG	8,36	0,076	15%	7,1	9,62								132			
(3) IFCC method; (149) Siemens (Dade, BN, Dimension)		8,77	0,74	8,4	10	0	CVPG	8,77	0,57	15%	7,45	10,1								10			
(3) IFCC method; (162) Siemens (Atellica)		8,49	0,24	2,8	22	0	CVPG	8,49	0,12	15%	7,21	9,77								22			
(3) IFCC method; (177) Mindray		9,97	0,86	8,7	12	0	CVPG	9,97	0,61	15%	8,47	11,5								12			

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/22 - Basic Clinical Chemistry - Serum

Deadline: 08.04.2022

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(21) ALP					364							358	352	98%							364	356	98%
Samples and groups	[µkat/L]																						
Sample A		8,92	0,76	8,6	364							358	354	99%	CRV	9,31	0,26	20%	7,44	11,2	364	357	98%
(3) IFCC method; (179) Siemens		8,57	0,49	5,8	15	0	CVPG	8,57	0,31	15%	7,28	9,86											
Other					1	0							1									1	
								1x 1/1, 1x 3/121, 2x 3/158, 3x 3/178							1x 1								
Sample B		3,51	0,25	7,0	364							358	354	99%	CRV	3,62	0,100	20%	2,89	4,35	364	362	99%
(3) IFCC method; (1) Abbott		3,59	0,16	4,5	90	0	CVPG	3,6	0,041	15%	3,06	4,14											
(3) IFCC method		3,51	0,25	7,0	363	0																363	
(3) IFCC method; (12) Beckman Coulter		3,82	0,22	5,6	5	0	CVPG	3,82	0,61	15%	3,24	4,4											
(3) IFCC method; (46) Erba Lachema		3,68	0,20	5,5	15	0	CVPG	3,68	0,13	15%	3,12	4,24											
(3) IFCC method; (49) BioVendor		3,47	0,26	7,5	11	0	CVPG	3,47	0,19	15%	2,94	4											
(3) IFCC method; (58) Beckman Coulter (AU)		3,83	0,17	4,3	45	0	CVPG	3,83	0,060	15%	3,25	4,41											
(3) IFCC method; (60) Roche		3,34	0,14	4,3	132	0	CVPG	3,34	0,030	15%	2,83	3,85											
(3) IFCC method; (149) Siemens (Dade, BN, Dimension)		3,46	0,26	7,6	10	0	CVPG	3,46	0,20	15%	2,94	3,98											
(3) IFCC method; (162) Siemens (Atellica)		3,41	0,11	3,1	22	0	CVPG	3,41	0,055	15%	2,89	3,93											
(3) IFCC method; (177) Mindray		3,84	0,30	7,9	12	0	CVPG	3,84	0,22	15%	3,26	4,42											
(3) IFCC method; (179) Siemens		3,44	0,20	5,7	15	0	CVPG	3,44	0,12	15%	2,92	3,96											
Other					1	0							1										1
								1x 1/1, 1x 3/121, 2x 3/158, 3x 3/178							1x 1								
(22) alpha-amylase					346							5	5	100%							341	337	99%
Samples and groups	[µkat/L]																						
Sample A		4,62	0,28	6,0	346							5	5	100%							341	338	99%
(1) IFCC method		4,62	0,27	5,9	339	0									CRV	4,59	0,13	15%	3,9	5,28		339	
(1) IFCC method; (149) Siemens (Dade, BN, Dimension)		5,52	0,04	0,89	5	0	CVPG	5,52	0,14	8,8%	5,03	6,01											
Other					2	0																	2
															2x 99								
Sample B		5,44	0,34	6,3	346							5	5	100%							341	338	99%
(1) IFCC method		5,43	0,34	6,2	339	0									CRV	5,35	0,16	15%	4,54	6,16		339	
(1) IFCC method; (149) Siemens (Dade, BN, Dimension)		6,54	0,14	2,2	5	0	CVPG	6,54	0,40	8,8%	5,96	7,12											
Other					2	0																	2
															2x 99								
(23) AST					370							0									370	369	100%
Samples and groups	[µkat/L]																						
Sample A		4,28	0,17	4,1	370							0			CRV	4,22	0,096	15%	3,58	4,86	370	370	100%
(1) IFCC method		4,28	0,17	4,1	370	0																	370
Sample B		1,78	0,08	4,8	370							0			CRV	1,771	0,045	15%	1,5	2,04	370	369	100%
(1) IFCC method		1,78	0,08	4,8	370	0																	370
(24) ALT					369							0									369	349	95%
Samples and groups	[µkat/L]																						
Sample A		1,59	0,11	6,8	369							0			CRV	1,536	0,036	15%	1,3	1,77	369	349	95%
(1) IFCC method		1,59	0,11	6,8	369	1																	369
Sample B		2,21	0,13	5,8	369							0			CRV	2,213	0,051	15%	1,88	2,55	369	369	100%

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/22 - Basic Clinical Chemistry - Serum

Deadline: 08.04.2022

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(24) ALT					369							0									369	349	95%
Samples and groups	[µkat/L]																						
Sample B		2,21	0,13	5,8	369							0	CRV	2,213	0,051	15%	1,88	2,55		369	369	100%	
(1) IFCC method		2,21	0,13	5,8	369	0																369	
(26) CK					332							0									332	330	99%
Samples and groups	[µkat/L]																						
Sample A		3,31	0,17	5,1	332							0	CRV	3,407	0,089	20%	2,72	4,09		332	331	100%	
(1) IFCC method		3,31	0,17	5,1	332	0																332	
Sample B		6,73	0,43	6,4	332							0	CRV	7,12	0,18	20%	5,69	8,55		332	330	99%	
(1) IFCC method		6,73	0,43	6,4	332	0																332	
(27) gamma-GT					367							0									345	338	98%
Samples and groups	[µkat/L]																						
Sample A		1,64	0,07	4,3	367							0									345	340	99%
(1) IFCC method		1,64	0,06	3,8	344	0							CRV	1,696	0,044	15%	1,44	1,96				344	
(1) IFCC method; (162) Siemens (Atellica)		1,49	0,06	4,1	22	0	CVPG	1,49	0,032	11%	1,32	1,66										1	
Other					1	0																	1
Sample B		1,28	0,05	4,1	367							0									345	341	99%
(1) IFCC method		1,28	0,04	3,7	344	0							CRV	1,32	0,038	15%	1,12	1,52				344	
(1) IFCC method; (162) Siemens (Atellica)		1,17	0,06	5,5	22	0	CVPG	1,17	0,033	11%	1,04	1,3										1	
Other					1	0																	1
(28) LD					270							0									270	270	100%
Samples and groups	[µkat/L]																						
Sample A		6,68	0,20	3,0	270							0	CRV	6,59	0,16	18%	5,4	7,78		270	270	100%	
(3) IFCC method		6,68	0,20	3,0	270	0																270	
Sample B		6,10	0,18	3,0	270							0	CRV	6,04	0,13	18%	4,95	7,13		270	270	100%	
(3) IFCC method		6,10	0,18	3,0	270	0																270	
(29) Lipase					174							157	155	99%									0
Samples and groups	[µkat/L]																						
Sample A		0,549	0,04	7,5	174							157	155	99%									0
(0) Not specified; (1) Abbott		0,545	0,03	6,8	34	0	CVPG	0,545	0,016	24%	0,414	0,676										34	
(0) Not specified; (58) Beckman Coulter (AU)		0,546	0,03	6,7	25	0	CVPG	0,546	0,018	24%	0,414	0,678										25	
(0) Not specified; (60) Roche		0,542	0,02	4,5	68	0	CVPG	0,542	0,0073	24%	0,411	0,673										68	
(0) Not specified; (116) Sentinel Diagnostics		0,465	0,02	4,8	7	0	CVPG	0,465	0,022	24%	0,353	0,577										7	
(0) Not specified; (162) Siemens (Atellica)		0,581	0,03	5,5	16	0	CVPG	0,581	0,020	24%	0,441	0,721										16	
(0) Not specified; (179) Siemens		0,605	0,03	6,1	7	0	CVPG	0,605	0,036	24%	0,459	0,751										7	
Other					17	0																	0
																							3x 0/12, 3x 0/46, 4x 0/49, 3x 0/149, 3x 0/177, 1x 0/178
Sample B		1,20	0,08	6,9	174							157	157	100%									0
(0) Not specified; (1) Abbott		1,22	0,05	4,8	34	0	CVPG	1,22	0,024	24%	0,927	1,52										34	
(0) Not specified; (58) Beckman Coulter (AU)		1,24	0,05	4,8	25	0	CVPG	1,24	0,029	24%	0,942	1,54										25	

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/22 - Basic Clinical Chemistry - Serum

Deadline: 08.04.2022

Test	[unit]	Comparability										Traceability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(29) Lipase	[µkat/L]				174							157	155	99%									0	
Samples and groups																								
Sample B		1,20	0,08	6,9	174							157	157	100%									0	
(0) Not specified; (60) Roche		1,17	0,04	4,2	68	0	CVPG	1,17	0,015	24%	0,889	1,46											68	
(0) Not specified; (116) Sentinel Diagnostics		1,17	0,10	8,9	7	0	CVPG	1,17	0,10	24%	0,889	1,46											7	
(0) Not specified; (162) Siemens (Atellica)		1,30	0,04	3,4	16	0	CVPG	1,3	0,027	24%	0,988	1,62											16	
(0) Not specified; (179) Siemens Other		1,35	0,07	5,5	7	0	CVPG	1,35	0,072	24%	1,02	1,68											7	
					17	0																	0	
								3x 0/12, 3x 0/46, 4x 0/49, 3x 0/149, 3x 0/177, 1x 0/178																
(30) Cholinesterase	[µkat/L]				114							109	104	95%									0	
Samples and groups																								
Sample A		127	5,3	4,2	114							109	105	96%									0	
(1) Standard method		127	4,8	3,8	109	0	CVP	127	1,1	12%	111	143											109	
(1) Standard method; (162) Siemens (Atellica)		152	4,7	3,1	5	0	CVPG	152	13	12%	133	171											0	
Sample B		120	5,4	4,5	114							109	104	95%									0	
(1) Standard method		120	4,9	4,1	109	0	CVP	120	1,1	12%	105	135											109	
(1) Standard method; (162) Siemens (Atellica)		145	3,6	2,5	5	0	CVPG	145	10	12%	127	163											0	
(31) Albumin (elpho)	[-]				82							82	80	98%									0	
Samples and groups																								
Sample A		0,627	0,04	7,2	82		CVP	0,627	0,012	15%	0,532	0,722											82	
(0) Not specified		0,627	0,04	7,2	82	0																	82	
Sample B		0,628	0,04	7,0	82		CVP	0,628	0,012	15%	0,533	0,723											82	
(0) Not specified		0,628	0,04	7,0	82	0																	82	
(32) gamma-globuline (elpho)	[-]				82							82	81	99%									0	
Samples and groups																								
Sample A		0,134	0,01	10	82		CVP	0,134	0,037	30%	0,093	0,175											82	
(0) Not specified		0,134	0,01	10	82	0																	82	
Sample B		0,136	0,01	11	82		CVP	0,136	0,039	30%	0,095	0,177											82	
(0) Not specified		0,136	0,01	11	82	0																	82	
(35) alpha-amylase pancreatic	[µkat/L]				107							107	106	99%									0	
Samples and groups																								
Sample A		3,89	0,17	4,4	107		CVP	3,89	0,041	18%	3,18	4,6											107	
(1) With IFCC calibration		3,89	0,17	4,4	107	0																	107	
Sample B		4,66	0,22	4,6	107		CVP	4,66	0,051	18%	3,82	5,5											107	
(1) With IFCC calibration		4,66	0,22	4,6	107	0																	107	
(36) Calcium ionised	[mmol/L]				57							57	54	95%									0	
Samples and groups																								
Sample A		1,05	0,03	3,5	57		CVP	1,05	0,012	10%	0,945	1,16											57	
(2) Direct ISE		1,05	0,03	3,6	53	0																	53	
Other					4	0																	4	
Sample B		1,90	0,07	3,9	57		CVP	1,9	0,024	10%	1,71	2,09											57	
								1x 0, 3x 1															54	

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS2/22 - Basic Clinical Chemistry - Serum

Deadline: 08.04.2022

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(36) Calcium ionised	[mmol/L]				57							57	54	95%									0
Samples and groups																							
Sample B		1,90	0,07	3,9	57	CVP	1,9	0,024	10%	1,71	2,09	57	54	95%									0
(2) Direct ISE		1,90	0,07	3,8	53							53											
Other					4							4											
						1x 0, 3x 1																	

st_kn_np

End of report

Printed: 13.04.2022